Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for newly diagnosed advanced or recurrent endometrial cancer: Japan subset from the phase III DUO-E trial
Journal of Gynecologic Oncology · 2025
DOI: 10.3802/jgo.2025.36.e118 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Gynecologic Oncology, 2025. Verfasst von Shin Nishio und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Kurume University School of Medicine, Kurume, Japan. shinshin@med.kurume-u.ac.jp. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Endometrial Neoplasms, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AstraZeneca.
Abstract (Originalsprache)
OBJECTIVE: DUO-E/GOG-3041/ENGOT-EN10 (NCT04269200) demonstrated statistically significant and clinically meaningful progression-free survival (PFS) improvement with durvalumab plus carboplatin/paclitaxel, followed by durvalumab with or without olaparib, vs. carboplatin/paclitaxel alone (intention-to-treat [ITT] population) in patients with newly diagnosed advanced or recurrent endometrial cancer. We evaluated efficacy and safety in the Japan subset of DUO-E. METHODS: Patients with newly diagnosed International Federation of Gynecology and Obstetrics stage III/IV or recurrent endometrial cancer were randomized 1:1:1 to control arm (carboplatin/paclitaxel + durvalumab placebo [6 cycles] followed by durvalumab placebo + olaparib placebo), durvalumab arm (carboplatin/paclitaxel + durvalumab [1,120 mg every 3 weeks] [6 cycles] followed by durvalumab [1,500 mg every 4 weeks] + olaparib placebo), or durvalumab + olaparib arm (carboplatin/paclitaxel + durvalumab [6 cycles] followed by durvalumab + olaparib [300 mg twice a day]). Dual primary endpoints were investigator-assessed PFS for durvalumab and durvalumab + olaparib arms vs. control. This prespecified exploratory analysis evaluated PFS and safety in the Japan subset. RESULTS: In the Japan subset (n=88) PFS favored durvalumab (hazard ratio=0.61, 95% confidence interval [CI]=0.32-1.12) and durvalumab + olaparib (0.44, 95% CI=0.22-0.85) vs. control; median PFS was 9.9 and 15.1 vs. 9.5 months, and the 18-month PFS rate was 37.0% and 42.1% vs. 22.2%, respectively. The safety profile in the Japan subset was generally consistent with the full safety analysis set and the established profiles of the individual agents. CONCLUSION: Efficacy and safety in the Japan subset were generally consistent with outcomes in the DUO-E ITT population. This Japanese subset analysis of DUO-E supports carboplatin/paclitaxel + durvalumab followed by durvalumab with or without olaparib as new treatment options in patients with advanced or recurrent endometrial cancer and is the first to report on these regimens in Japanese patients alone.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Kurume University School of Medicine, Kurume, Japan. shinshin@med.kurume-u.ac.jp.
- Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
- Department of Gynecologic Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
- Department of Gynecology, Osaka International Cancer Institute, Osaka, Japan.
- Department of Obstetrics and Gynecology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
- Department of Gynecologic Oncology and Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
ORCID-Profile: Shin Nishio, Tadaaki Nishikawa, Masahiko Mori, Shoji Kamiura, Toshiyuki Sumi, Mayu Yunokawa, Yuichi Imai, Eiji Kondo, Kazuhiro Takehara, Hirokuni Takano, Wataru Kudaka, Nobuhiro Kado, Wataru Yamagami, Hidenori Kato, Koji Nishino, Tomoka Usami, Junzo Hamanishi, Masahiro Nii, Itsumi Takaya, Aikou Okamoto
Förderung
- AstraZeneca
Zitieren
APA
Nishio, S., Nishikawa, T., Mori, M., Kamiura, S., Sumi, T., Yunokawa, M., Imai, Y., Kondo, E., Takehara, K., Takano, H., Kudaka, W., Kado, N., Yamagami, W., Kato, H., Nishino, K., Usami, T., Hamanishi, J., Nii, M., Takaya, I., & Okamoto, A. (2025). Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for newly diagnosed advanced or recurrent endometrial cancer: Japan subset from the phase III DUO-E trial. Journal of Gynecologic Oncology. https://doi.org/10.3802/jgo.2025.36.e118
Vancouver
Nishio S, Nishikawa T, Mori M, Kamiura S, Sumi T, Yunokawa M, et al. Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for newly diagnosed advanced or recurrent endometrial cancer: Japan subset from the phase III DUO-E trial. Journal of Gynecologic Oncology. 2025. doi:10.3802/jgo.2025.36.e118
BibTeX
@article{Nishio2025,
author = {Nishio, Shin and Nishikawa, Tadaaki and Mori, Masahiko and Kamiura, Shoji and Sumi, Toshiyuki and Yunokawa, Mayu and Imai, Yuichi and Kondo, Eiji and Takehara, Kazuhiro and Takano, Hirokuni and Kudaka, Wataru and Kado, Nobuhiro and Yamagami, Wataru and Kato, Hidenori and Nishino, Koji and Usami, Tomoka and Hamanishi, Junzo and Nii, Masahiro and Takaya, Itsumi and Okamoto, Aikou},
title = {Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for newly diagnosed advanced or recurrent endometrial cancer: Japan subset from the phase III DUO-E trial},
journal = {Journal of Gynecologic Oncology},
year = {2025},
doi = {10.3802/jgo.2025.36.e118}
}
EUVIMED